NCT07295704Recruiting
Micropulse Laser in Treatment of Initial and Refractory Cases of Center-Involved Diabetic Macular Edema
Comparative Evaluation of Micropulse Laser in Treatment of Initial and Refractory Cases of Center-Involved Diabetic Macular Edema
Source: ClinicalTrials.gov · Last updated 22 Dec 2025
Brief summary (registry, in English)
This study aims to evaluate the effect of subthreshold 577 nm micropulse laser photocoagulation in the treatment of initial and refractory cases of Center-Involved Diabetic Macular Edema.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 50 (estimated)
- First submitted
- 6 Dec 2025
- Start date
- 15 Oct 2025
- Primary completion date
- 30 Mar 2026
- Lead sponsor
- The General Authority for Teaching Hospitals and Institutes
- Diseases
- Diabetic eye disease
- NCT number
- NCT07295704
What you commit to
- Study type: Observational
- Planned participants: 50
- From 15 Oct 2025 to the primary completion date, 30 Mar 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Intraocular surgery within 6months, including cataract or vitreoretinal operation.
Other illness
- Chronic renal failure or renal transplant because of diabetic nephropathy.
- Vitreomacular traction syndrome.
- Any condition that could interfere with optical coherence tomography (OCT) measurement or visual acuity.
Lab values
- Glycated hemoglobin (HbA1c) of more than 10%.
Other
- Monocular eyes.
- Epiretinal membrane.
- PRP within 4months before the treatment.
- Rubeosis iridis.
- Severe glaucoma.
- High-risk proliferative diabetic retinopathy.
- Poor dilation.
- Increased foveal avascular zone.
Who the study is looking for
- Age ≥18 years.
- Both sexes.
- Patients with type 1 or 2 diabetes mellitus (DM), best-corrected visual acuity (BCVA) of 20/400 or better, and center-involved DME \[defined as a central macular thickness (CMT) of \>250 but \<700µm measured by spectral-domain optical coherence tomography\].
- Patients with any level of non-proliferative diabetic retinopathy or proliferative diabetic retinopathy with adequate panretinal photocoagulation (PRP) and no signs of disease activity determined by fluorescein angiography (FA).
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| the General Authority for Teaching Hospitals and Institutes Coordinator of this site? Confirm its status | Cairo | Egypt | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.